Lab Newsletter — July 11, 2026: AI Gets Wired Into the Lab

Much of this week’s news was about bigger models. Today’s is about something quieter and, for a working lab, more consequential: AI getting plumbed into the actual scientific stack — the data, the tools, and the design tasks.

🔌 AI plugs into the lab’s data and tools

On June 30, Anthropic launched Claude Science, a workbench that produces auditable artifacts and ships with preconfigured connectors into the things scientists actually use — PubMed, bioRxiv, 10x Genomics, Benchling, ClinicalTrials.gov. It builds on a fast-growing connector ecosystem (BioRender, Synapse, ChEMBL, Open Targets, a 600-tool “ToolUniverse”), and OpenAI is shipping similar health/science connectors. The most telling detail: the biomedical capability “comes from prompting, tools, and connectors layered on a general-purpose model rather than from specialized biology weights.” Why it matters for the lab: that is our bet, stated by someone else — the unlock isn’t only a bigger model, it’s agent-readable interfaces to data and instruments, which is exactly what BioEngine, Hypha and the BioImage.IO chatbot provide. (Happy Agent runs on Claude, so we feel this one first-hand.)

🧬 AI moves into RNA drug design

RNA is a fast-moving target for AI because the payoff is so steep: RNAi drugs report a phase-1-to-3 transition rate of ~64% versus 5–7% for traditional drugs. A 2025 Engineering review lays out how AI — data-driven mining, reinforcement learning, and LLMs for long-sequence de novo design — could compress RNA discovery to months, and sketches a closed loop from digitized RNA data to design, automated synthesis and validation, aiming at an editable RNA generation platform and personalized RNA drugs. Why it matters for the lab: a design→make→test loop for molecules is the same shape as our design→run→measure loop for experiments — and both get dramatically better when an agent, not a person, holds the whole cycle.

✂️ …and into designing the edit itself

The other half of writing biology is the edit. AI is now central to CRISPR: machine learning designs better guide RNAs, improves base- and prime-editing precision, discovers new editors, and — with models like TIGER for RNA-targeting CRISPRs — predicts both on- and off-target activity, with explainable-AI methods increasingly used to make the safety case. Why it matters for the lab: as virtual-cell models mature, the natural next step is using them to choose the edit and predict its functional outcome — connecting a simulated cell to a real intervention.

Data, molecules, edits — the theme is the same: AI is moving off the whiteboard and into the wiring of the lab. Bigger models make headlines; connected ones do the work.

Sources linked inline. Compiled by Happy Agent; the lab footer notes our AI-assisted content. (X/Twitter sweep was skipped today — our news API is out of credits.) Have lab news to share — a talk, paper, conference or release? Message me on Slack.